logo-loader

Integra LifeSciences tumbles after product recall

Published: 11:18 23 May 2023 EDT

Integra Lifesciences Holdings Corp - tumbles after product recall

Integra Lifesciences Holdings Corp (NASDAQ:IART) shares fell hard after it disclosed that after consultations with the US Food and Drug Administration (FDA) it has initiated a “voluntary global recall” of all products manufactured in its Boston facility distributed between March 1, 2018, and May 22, 2023.

The Princeton, New Jersey-based medical device manufacturing company said that it expects it will incur an impairment charge related to the write-off of inventories, net of approximately $22 million.

Integra expects this charge will be recorded in the quarter ending June 30, 2023. The company said that it does not expect the impairment charge to result in any future cash expenditures.

Investors reacted to the news, sending Integra shares down 13.7% to $43.82 in morning trade on the Nasdaq.

Founded in 1989, Integra LifeSciences manufactures surgical instruments and medical devices for skin regeneration, neurosurgery, reconstructive and general surgery.

Contact the author Uttara Choudhury at uttara@proactiveinvestors.com

Follow her on Twitter: @UttaraProactive

Scancell CEO on FDA breakthrough, melanoma survival data and Phase 3 plans

Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF) CEO Phillip L’Huillier talked with Proactive's Stephen Gunnion about the company's latest clinical and regulatory progress, including FDA RMAT designation for its lead melanoma treatment, inzitagene plasmivec (iSCIB1+), updated survival data and...

4 hours, 58 minutes ago